Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 30 to June 3, 2008.

"The breadth of data presented at ASCO highlights the promise nimotuzumab holds for a diverse group of oncology patients," said David Allan, Chairman and CEO of YM BioSciences. "In each of these trials, results further demonstrated the unique potential for nimotuzumab to be an effective EGFR-targeting antibody without deleterious side-effects observed with the other drugs in its class."

"Phase III trial of nimotuzumab for the treatment of newly diagnosed

diffuse intrinsic pontine gliomas in children and adolescents" (Abstract

number 2058):

This poster reported data from a multi-centre Phase III study evaluating the feasibility and efficacy of nimotuzumab as the primary treatment for these patients. Between March 2006 and August 2007, 42 patients aged 3 to 16 years (median 7 years) were enrolled in this study, with 41 patients evaluable for response. The primary endpoint for the trial is median progression free survival at six months after diagnosis. Secondary endpoints include overall survival, response rate, toxicity and quality of life.

The poster presentation described preliminary results including that the median progression free survival was 5.9 months, that the median
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ands, December 2 Pepscan Holding N...using on protein mimicking,technology for the gene... it,has appointed Wim E.M. Mol, Ph.D. as new Chief...ponsible for all of Pepscans corporate functions a...of the company. He brings to,Pepscan more than 20 ...
(Date:12/2/2009)...RNewswire/ -- S*BIO Pte Ltd today announced data p...518, at The American Society of Hematology 51st An...Data will be presented on the clinical results fro...iling its safety, tolerability and pharmacokinetic...nging from 100 to 600 mg. These doses were adminis...
(Date:12/2/2009)...swire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ...rmaceutical company focused on endocrine therapy a...d Drug Administration (FDA) has granted Fast Track...hibitor compound, perifosine (KRX-0401), for the t...Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), ...
(Date:12/2/2009)...Newswire/ -- According to the National Institute o...agnosed with diabetes already have some stage of d... to the retina caused by leaky blood vessels, is a...and is one of the most feared diabetic complicatio...,ve had diabetes for 10 years or more will experie...
Breaking Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
... The 2009 Personalized Me...riety of stakeholders in both the public and priva...allenges facing those involved in the development ... Baltimore, MD (PRWEB) February ...e Conference is a full two day conference set to ...
... Strong Pipeline and Superior Distribution System ..., NEW YORK, Feb. 10 DuPont Group (NYSE: DD ) Vi...DuPont business Pioneer Hi-Bred to grow its global...in 2009 and he committed to grow compounded annual...on segment an average of at least 15 percent over ...
... ANN ARBOR, Mich., Feb. 10 Compendia Bioscience, ...tive year, including a 100 percent renewal rate fr...itments from existing customers, including multi-y...ical companies, led to a greater than 300% revenue...ia,s core product, Oncomine(TM), has become a stan...
Other Biology Technology:The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 2The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability 2
(Date:12/2/2009)...People who smoke their first cigarette within minu...inine, a by-product of nicotine when processed by ... of the number of cigarettes smoked. , "Since...g cancer, our results suggest that smokers who smo...isk for lung cancer," said researcher Joshua E. Mu...
(Date:12/2/2009)...rance of a cancer-free status did not prompt peopl...aphy (CT) lung-cancer screening program to pick up...udy published in Cancer Epidemiology, Biomarkers ...on for Cancer Research. The December issue contain...hould negate widespread concern in the lung screen...
(Date:12/2/2009)... the University of Georgia College of Veterinary M...hat could open new avenues for treating Ichthyopht...-celled protozoan parasite that commonly attacks f...equencing, researchers found that Ich harbors two ...eroides, which are usually found free-living, and ...
Breaking Biology News(10 mins):Increased nicotine levels detected in those who light-up earlier 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3Fructose May Raise Blood Pressure 60389 1Fructose May Raise Blood Pressure 60389 2Science Finds Healing in Halloween Horrors 60387 1Science Finds Healing in Halloween Horrors 60387 2Science Finds Healing in Halloween Horrors 60387 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 1AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 4AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 5AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 6AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 7AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 8AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 9AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 10AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 11AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 12AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 13AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 14AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 15AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 16AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 17AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 18
...ng muscle regeneration, which is a natural respons...adult muscle stem cells (satellite cells) to shift...sue. Although the signaling pathways controlling ...se signals lead to altered chromatin structure rem...urnham Institute for Medical Research in La Jolla,...
...esda, MD - The December 15th issue of Biophysical ...now available online. Topics of interest include c...ity, optical trapping; single-molecule, ADP-bound ...Volume 93, Issue 12, December 15, 2007 , , Eff...n Situ Cross-Bridge Dynamics in Rat Hearts , , J...
...researchers at The University of Nottingham are te... institutions around the region, to work on pionee...nto a mobile biosensor, to detect the use of illeg...nufacturing process to make titanium golf clubs mo...orative studentships, currently underway in the Ea...
Other Biology News:Media highlights in the Dec. 15 issue of Biophysical Journal 2Media highlights in the Dec. 15 issue of Biophysical Journal 3Media highlights in the Dec. 15 issue of Biophysical Journal 4
...combinant protein that has been shown to help main...NA by reverse transcription, in vitro RNA transcri...nhibitor tightly binds RNases in a 1:1 ratio. It i... RNase A, RNase B, RNase C, and human placental RN...
FastStart High Fidelity PCR System, dNTPack (Not available in US) from Roche Applied Science
RNase Inhibitor from Applied Biosystems
HEPA Filtered Single Chamber Water Jacketed Incubator, CO2/O2 IR, 115V, 50/60 Hz from Thermo Scientific
Biology Products: